ArticleDrug design, development and therapy2026
Interpretable Machine Learning Identifies Hub Biomarkers of Renal Fibrosis and Their Potential Medical Applications.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal fibrosis is a crucial pathogenic driver of chronic kidney disease (CKD). However, its heterogeneous limits accurate assessment by renal biopsy. The study aimed to identify accurate diagnostic biomarkers and potential therapeutic targets for renal fibrosis. Methods: We analyzed renal fibrosis transcriptomic datasets from the GEO database to identify differentially expressed genes (DEGs). Hub genes were selected through the Least Absolute Shrinkage and Selection Operator (LASSO) regression, with their association to immune infiltration subsequently analyzed using CIBERSORT. Interpretable machine learning models, specifically eXtreme Gradient Boosting (XGBoost) and Deep Neural Network (DNN), were developed for sample classification, with their interpretability and key biomarker contribution assessed through Shapley Additive Explanations (SHAP) analysis. The predicted hub genes were validated using histological staining, Western blot (WB) experiments, and functional cellular assays in rat renal fibroblast cells and mouse renal fibrosis models. Finally, potential therapeutic drugs targeting the hub genes were identified through molecular docking. Results: We identified 26 fibrosis-related genes for renal fibrosis and established their correlations with inflammatory and immune infiltration. Machine learning models demonstrated high diagnostic accuracy (XGBoost: 96%; DNN:92%). SHAP analysis highlighted AGR2 and DOCK2 as top predictors. Subsequent experimental validation confirmed their significant upregulation and functional involvement in fibrotic processes. Molecular docking identified several existing drugs such as Dexamethasone and Ciclosporin as potential AGR2-targeting agents. Conclusion: This study identifies AGR2 and DOCK2 as novel biomarkers and therapeutic targets for renal fibrosis, highlighting their dual potential for diagnostic application and targeted therapy development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.